NASDAQ · BDMDW

Baird Medical Investment Holdings Ltd Warrant (BDMDW)

$0.0301−2.90%
Close Sep 23, 2026 · split-adjusted
Sep 23, 2026$0.03▼ 61.06% in range
Sep 29, 2025Low $0.03 · High $0.19Sep 23, 2026
What changed · written from our data
As of Sep 28, 2026

Baird Medical Investment Holdings Ltd Warrant closed at $0.03 on Sep 23, down 2.90%, within 0.0% of its lowest close since Oct 2. Volume of 9.0K shares was 1.27× its 20-day average (above normal).

Split-adjusted performance: -24.8% over one month.

Short interest was 16.9K shares at the Sep 15 settlement, up 17.5% from the prior report (9.8 days to cover).

Market cap$346.1K11.5M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yieldNone
Range since Oct 20.03 – 0.19−83.9% from high
Volume9.0K1.27× 20-day avg
Volatility · 60d215.6%Annualised
Short % of float—9.9 days to cover
Net cash—
Next earnings—Not scheduled
Split-adjusted performance
1W −2.9%1M −24.8%3M —6M —YTD −49.8%1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within industry

Not enough peers to rank

6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—

Short interest

Details →
Shares short16.9K+17.5% vs prior
Days to cover9.9Settled Sep 15
% of float—
Short vol. 10d—of daily volume

News about Baird Medical Investment Holdings Ltd Warrant

All news →

No recent articles focused on Baird Medical Investment Holdings Ltd Warrant.

Quick answers

What does Baird Medical Investment Holdings Ltd Warrant do?
Baird Medical Investment Holdings Ltd is a specialized healthcare innovator dedicated exclusively to thyroid-related diseases and a microwave ablation (MWA) medical device manufacturer and provider in China. The company combines clinical expertise with technologies to develop non-invasive treatment solutions.
What is BDMDW's market cap?
$346.15K, based on the Sep 23 close of $0.03.

About Baird Medical Investment Holdings Ltd Warrant

Baird Medical Investment Holdings Ltd is a specialized healthcare innovator dedicated exclusively to thyroid-related diseases and a microwave ablation (MWA) medical device manufacturer and provider in China. The company combines clinical expertise with technologies to develop non-invasive treatment solutions. Its proprietary MWA medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Its core activities include the development and commercialization of thyroid microwave ablation systems and an active R&D pipeline of AI-integrated robotic systems, integrating hardware, software, and system-based solutions.

146 employeesListed Oct 2, 2024

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology